These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

584 related items for PubMed ID: 7582401

  • 1. Effects of fluvastatin, a new inhibitor of HMG-CoA reductase, and niceritrol on serum lipids, lipoproteins and cholesterol ester transfer activity in primary hypercholesterolemic patients.
    Sasaki J, Yamamoto K, Kobori S, Setoguchi Y, Sato Y, Matsunaga A, Shichiri M, Sakai T, Kono S, Arakawa K.
    Int J Clin Pharmacol Ther; 1995 Jul; 33(7):420-6. PubMed ID: 7582401
    [Abstract] [Full Text] [Related]

  • 2. Effects of D-003, a mixture of long-chain aliphatic primary acids, fluvastatin and the combined therapy of D-003 plus fluvastatin on the lipid profile of normocholesterolemic rabbits.
    Mendoza S, Gamez R, Mas R, Goicochea E.
    Int J Tissue React; 2003 Jul; 25(3):81-9. PubMed ID: 14756189
    [Abstract] [Full Text] [Related]

  • 3. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
    Alvarez-Sala LA, Cachofeiro V, Masana L, Suarez C, Pinilla B, Plana N, Trias F, Moreno MA, Gambus G, Lahera V, Pintó X.
    Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
    [Abstract] [Full Text] [Related]

  • 4. Impact of fluvastatin on hyperlipidemia after renal transplantation.
    Tokumoto T, Tanabe K, Ishida H, Shimmura H, Ishikawa N, Goya N, Akiba T, Toma H.
    Transplant Proc; 2004 Sep; 36(7):2141-4. PubMed ID: 15518777
    [Abstract] [Full Text] [Related]

  • 5. Fluvastatin in combination with other lipid-lowering agents.
    Jokubaitis LA.
    Br J Clin Pract Suppl; 1994 Dec; (77):28-32. PubMed ID: 19496270
    [Abstract] [Full Text] [Related]

  • 6. Fluvastatin in combination with other lipid-lowering agents.
    Jokubaitis LA.
    Br J Clin Pract Suppl; 1996 Jan; 77A():28-32. PubMed ID: 8729588
    [Abstract] [Full Text] [Related]

  • 7. Low-dose effect of simvastatin (MK-733) on serum lipids, lipoproteins, and apolipoproteins in patients with hypercholesterolemia.
    Saku K, Sasaki J, Arakawa K.
    Clin Ther; 1989 Jan; 11(2):247-57. PubMed ID: 2736571
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of once-daily vs twice-daily dosing with fluvastatin, a synthetic reductase inhibitor, in primary hypercholesterolemia.
    Insull W, Black D, Dujovne C, Hosking JD, Hunninghake D, Keilson L, Knopp R, McKenney J, Stein E, Troendle AJ.
    Arch Intern Med; 1994 Nov 14; 154(21):2449-55. PubMed ID: 7979841
    [Abstract] [Full Text] [Related]

  • 9. Comparison of combined statin-fibrate treatment to monotherapy in patients with mixed hyperlipidemia.
    Kłosiewicz-Latoszek L, Szostak WB, Grzybowska B, Białobrzeska-Paluszkiewicz J, Wiśniewska B, Stolarska I.
    Kardiol Pol; 2004 Jun 14; 60(6):567-77. PubMed ID: 15334157
    [Abstract] [Full Text] [Related]

  • 10. Effect of paraoxonase 1 polymorphisms on the response of lipids and lipoprotein-associated enzymes to treatment with fluvastatin.
    Christidis DS, Liberopoulos EN, Kakafika AI, Miltiadous GA, Liamis GL, Kakaidi B, Tselepis AD, Cariolou MA, Elisaf MS.
    Arch Med Res; 2007 May 14; 38(4):403-10. PubMed ID: 17416287
    [Abstract] [Full Text] [Related]

  • 11. Genetic determinants of responsiveness to the HMG-CoA reductase inhibitor fluvastatin in patients with molecularly defined heterozygous familial hypercholesterolemia.
    Leitersdorf E, Eisenberg S, Eliav O, Friedlander Y, Berkman N, Dann EJ, Landsberger D, Sehayek E, Meiner V, Wurm M.
    Circulation; 1993 Apr 14; 87(4 Suppl):III35-44. PubMed ID: 8462179
    [Abstract] [Full Text] [Related]

  • 12. Effect of fluvastatin on plasma apolipoprotein-B-containing particles, including lipoprotein(a). European Fluvastatin Study Group.
    Dallongeville J, Fruchart JC, Pfister P, Bard JM.
    J Intern Med Suppl; 1994 Apr 14; 736():95-101. PubMed ID: 7986315
    [Abstract] [Full Text] [Related]

  • 13. Fluvastatin improves lipid abnormalities in patients with moderate to advanced chronic renal insufficiency.
    Samuelsson O, Attman PO, Knight-Gibson C, Mulec H, Weiss L, Alaupovic P.
    Am J Kidney Dis; 2002 Jan 14; 39(1):67-75. PubMed ID: 11774104
    [Abstract] [Full Text] [Related]

  • 14. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
    Derosa G, Cicero AE, Bertone G, Piccinni MN, Ciccarelli L, Roggeri DE.
    Clin Ther; 2004 Oct 14; 26(10):1599-607. PubMed ID: 15598476
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Effect of fluvastatin or bezafibrate on the distribution of high density lipoprotein subpopulations in patients with familial hypercholesterolemia.
    Hailer S, Pogarell O, Keller C, Wolfram G.
    Arzneimittelforschung; 1996 Sep 14; 46(9):879-83. PubMed ID: 8876936
    [Abstract] [Full Text] [Related]

  • 17. Effects of bezafibrate and of 2 HMG-CoA reductase inhibitors on lipoprotein (a) level in hypercholesterolemic patients.
    Branchi A, Rovellini A, Fiorenza AM, Sommariva D.
    Int J Clin Pharmacol Ther; 1995 Jun 14; 33(6):345-50. PubMed ID: 7582386
    [Abstract] [Full Text] [Related]

  • 18. Elderly patients with hypercholesterolaemia: a double-blind study of the efficacy, safety and tolerability of fluvastatin.
    Lye M, Valacio R, Reckless JP, Ghosh AK, Findlay IN, Ghosh MK, Passmore AP, Fulcher RA.
    Coron Artery Dis; 1998 Jun 14; 9(9):583-90. PubMed ID: 9861520
    [Abstract] [Full Text] [Related]

  • 19. The effect of fluvastatin on the pharmacokinetics and pharmacodynamics of ezetimibe.
    Reyderman L, Kosoglou T, Cutler DL, Maxwell S, Statkevich P.
    Curr Med Res Opin; 2005 Aug 14; 21(8):1171-9. PubMed ID: 16083526
    [Abstract] [Full Text] [Related]

  • 20. Effects of niceritrol (pentaerythritol tetranicotinate) on plasma lipoprotein concentration: increment of high density lipoprotein(HDL) cholesterol and HDL-cholesterol/low density lipoprotein cholesterol ratio in hypo-high density lipoproteinemia.
    Oida K, Nakai T, Tamai T, Kutsumi Y, Kobayashi T, Hayashi T, Yamada S, Takeda R.
    Artery; 1982 Aug 14; 10(4):266-85. PubMed ID: 7181672
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.